Alkermes falls as new insider sales hit tape after Avadel acquisition close
Alkermes (ALKS) shares are sliding after fresh Form 4 filings showed additional insider selling in early April, extending a post-deal reset following the Avadel acquisition close. The stock is down about 3.1% to $32.89 as investors weigh insider supply and near-term acquisition-related costs.
1. What’s moving the stock today
Alkermes shares are under pressure today as investors react to newly disclosed insider transactions, with recent Form 4 filings showing additional selling in the first days of April. The incremental insider supply is landing on a stock that has been digesting major corporate activity and near-term integration expenses, contributing to a risk-off tone in trading.
2. The key disclosures investors are reacting to
A Form 4 filing disclosed an executive vice president sale of 9,000 shares executed on April 1, 2026 at a weighted average price around $35.51. Another Form 4 filed more recently disclosed an additional sale of 2,034 shares by an executive, reinforcing the insider-selling narrative even as the company transitions into its expanded sleep-medicine footprint.
3. Bigger backdrop: Avadel deal is now closed
The company completed its acquisition of Avadel Pharmaceuticals, adding the narcolepsy franchise and expanding Alkermes’ presence in sleep medicine. Alkermes also flagged that it expects to record about $40 million of transaction-related costs in the first quarter of 2026, a near-term headwind that can amplify sensitivity to any negative tape signals such as insider selling.
4. What to watch next
Traders will be looking for signs that insider activity stabilizes and for clearer read-through on integration execution and the sleep-medicine portfolio’s revenue trajectory. Any incremental updates on the orexin program and commercialization progress for the acquired assets could quickly reframe the narrative, but until then, the stock may remain headline-driven around filings and near-term cost items.